The market potential for Alzheimer's diagnostics (screening and monitoring therapy) is estimated to be $6-800M in the US alone. Quite frankly, I didn't acquire this stock with the drug therapy in mind...rather to play the diagnostic products. Unless NYMX gets a BIG Pharma partner to develop any compound, they should stick to the diagnostic side. The Serex thing gives them a number of new and exciting options there. Hey, just one investors opinion...p.s. love your screen name.